Aim: The objective of this study was to elucidate the effects of tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), interleukin 2 (IL-2), interleukin 6 (IL-6), and interleukin 8 (IL-8) on the expression of soluble endothelial protein C receptor (sEPCR) in the pathogenesis of thrombotic complications after hematopoietic stem cell transplantation (HSCT).
Methods: The relationship between plasma concentrations of proinflammatory cytokines (TNF-α, IL-1β, IL-2, IL-6, and IL-8) and sEPCR was evaluated in 32 consecutive allogeneic hematopoietic stem cell—transplanted patients prior to conditioning regimen and randomly once between +5 and +30 days after transplantation and compared these results with 20 healthy controls.
Results: Soluble endothelial protein C receptor levels did not indicate any significant difference between pre- and posttransplantation period, and sEPCR levels showed a significantly negative correlation between IL-6 and IL-8 (sEPCR and IL-6, r = —.43, P < .01; sEPCR and IL-8, r = —.57, P < .01). There was no correlation between sEPCR levels and TNF-α, IL-1β, or IL-2 (sEPCR and TNF-α, r = —.13, P > .05; sEPCR and IL-1β, r = —.1, P ≥ .05; sEPCR and IL-2, r = —.07, P > .05).
Conclusions: Our results suggest that the production of sEPCR was not affected by allogeneic HSCT. Soluble endothelial protein C receptor did not show any positive correlation between these proinflammatory cytokines (TNF-α, IL-1β, IL-2, IL-6, and IL-8), on the contrary a significantly negative correlation was determined between sEPCR and either IL-6 or IL-8. This negative correlation may be a protective mechanism in the pathway of protein C activation.
McDonald GB, Sharma P., Matthews DE, Shulman HM, Thomas EDThe clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation. 1985;39(6):603-608.
2.
Holler E., Kolb HJ, Hiller E., et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989;73(7):2018-2024.
3.
Scrobohaci ML , Drouet L., Monem-Mansi A., et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res. 1991;63(5):509-519.
4.
Faioni EM, Krachmalnicoff A., Bearman SI, et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of liver . Blood. 1993;81(12):3458-3462.
5.
Gordon B., Haire W., Kessinger A., Duggan M., Armitage J.High frequency of antithrombin III and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant . 1991;8(6):497-502.
6.
Harper PL, Jarvis J., Jennings I., Luddington R., Marcus REChanges in the natural anticoagulants following bone marrow transplantation . Bone Marrow Transplantation. 1990; 5(1):39-42.
7.
Shulman HM, Hinterberger W.Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation . Bone Marrow Transplant. 1992;10(3):197-214.
8.
Ertem M., Akar N. Factor V Leiden mutation as a predisposing factor for veno-occlusive disease following BMT. Bone Marrow Transplant. 2000;25(10):1110-1111.
9.
Duggan C., Schmidt M., Lawler M., et al. The prothrombin gene variant G20210A but not factor V Leiden may be associated with veno-occlusive disease following BMT. Bone Marrow Transplant. 1999;24(6):693-694.
10.
Park YD, Yasui M., Yoshimoto T., et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant . 1997; 19(9):915-920.
11.
Bearman SIVeno-occlusive disease of the liver. Opin Oncol. 2000;12:103-109.
12.
Esmon CTThe protein C anticoagulant pathway. Arterioscler Thromb. 1992;12(2):135-145.
13.
Kurosawa S. , Stearns-Kurosawa DJ, Hidari N., Esmon CTIdentification of functional endothelial protein C receptor in human plasma. J Clin Invest. 1997;100(2):411-418.
14.
Regan LM, Stearns-Kurosawa DJ, Kurosawa S., Mollica J., Fukodome K., Esmon CTThe endothelial protein C receptor. Inhibition of activated protein C anticoagulant functions without modulation of reaction with proteinase inhibitors . J Biol Chemist. 2000;271(29):17499-17503.
15.
Xu J., Qu D., Esmon NL, Esmon CTMetalloproteolytic release of endothelial cell protein C receptor . J Biol Chem. 2000;275(8): 6038-6044.
16.
Ulu A., Egin Y., Akar N.The correlation between soluble endothelial protein c receptor (sEPCR) and tumor necrosis factor-alpha (TNF-α) levels in vivo. Turk J Hematol. 2008; 25:108-109.
17.
Nan B., Lin P., Lumsden AB, Yao Q., Chen C.Effects of TNF-α and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Thromb Res. 2005;115(5):417-426.
18.
Schots R., Kaufman L., Van R., et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003 ;17(6):1150-1156.
19.
Holler E., Kolb HJ, Möller A., et al. Increased serum levels of tumor necrosis factor-α precede major complications of bone marrow transplantation. Blood . 1990;75(4):1011-1016.
20.
Chasty RC, Lamb WR, Gallati H., Roberts TE, Brenchley PEC, Yin JASerum cytokine levels in patients undergoing bone marrow transplantation . Bone Marrow Transplant. 1993;12(4): 331-336.
21.
Schwaighofer H., Herold M., Schwartz T., et al. Serum levels of interleukin-6, interleukin-8 and C-reactive protein after human allogeneic bone marrow transplantation . Transplantation. 1994;58(4):430-436.
22.
Remberger M. , Ringden O.Serum levels of cytokines after bone marrow transplantation: increased IL-8 during severe veno-occlusive disease of the liver. Eur J Haematol. 1997; 59(4):254-262.
23.
McDonald GB , Sharma P., Matthews DE, Shulman HM, Thomas EDVenocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984 ;4(1):116-122.
24.
McDonald GB , Hinds MS, Fischer LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255-267.
25.
Remberger M. , Ringden O.Increased levels of soluble interleukin-2 receptor in sinusoidal obstruction syndrome of the liver after allogeneic bone marrow transplantation. Transplantation. 1995; 60(11):1293-1299.
26.
Iguchi A., Kobayashi R., Yoshida M., et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant. 2001 ;27(11):1173-1180.
27.
Ferra C., De Sanjose S., Gallardo D., et al. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica. 1998;83(12):1082-10877.
28.
Imamura M., Hashino S., Kobayashi H., et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-γ, and tumor necrosis factor-α in graft-versus-host disease. Bone Marrow Transplant. 1994;13(6):745-751.
29.
Wang XS, Shi Q., Williams LA, et al. Serum Interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008;113(8): 2102-2109.
30.
Caharreau B. , Coupel S., Goret F., Pourcel C., Soulilou JPAssociation of glucocorticoids and cyclosporin A or rapamycin prevents E-selectin and IL-8 expression during LPS- and TNFalphamediated endothelial cell activation . Transplantation. 2000; 69(5):945-953.
31.
Gugliotta L. , Catani L., Vinelli L., et al. High plasma levels of tumor necrosis factor-α may be predictive of sinusoidal obstruction syndrome in bone marrow transplantation. Blood. 1994;83(8):2385-2386.
32.
Tanaka J., Imamura M., Kasai M., et al. Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation . Br J Haematol. 1993;85(3):558-565.
33.
Nawroth PP, Stern DMModulation of endothelial cell hemostatic properties by tumor necrosis factor . J Exp Med. 1986;163(3): 740-745.
34.
Nawroth PP, Handley DA, Esmon CT, Stern DMInterleukin I induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A.1986;83(10):3460-3464.
35.
Bauer KA, Ten Cate H., Barzegar S., Spriggs DR, Sherman ML, Rosenberg RDTumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 1989 ;74(1):165-172.
Castenskiold EC, Kelsey SM, Collins PW, et al. Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse. Bone Marrow Transplant . 1995;15(6):879-884.
38.
Coppell JA, Brown SA, Perry D.Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Reviews. 2003;17(2):63-70.
